Replay

Replay is a genome writing company dedicated to advancing genomic medicine by developing and delivering large DNA constructs. The company focuses on addressing monogenic diseases and other complex conditions. Founded in July 2022, Replay is led by a team of experts, including CEO Lachlan MacKinnon and notable figures from the biotechnology field.

Headquartered in San Diego, CA, and London, UK, Replay employs a team of 11-50 people. The company has developed several innovative technologies, including synHSV™, a high-capacity herpes simplex virus vector for gene therapy, and uCell, a hypoimmunogenic cell therapy platform. Their proprietary platforms, DropSynth™ and LASR™, enhance genome writing and enzyme optimization. Replay has established multiple gene therapy product companies targeting various diseases, including rare genetic disorders and solid tumors.